Verified factor-similar pair

IVOV vs VBR

These two ETFs meet the same FF6 US comparison criteria: US-listed equity ETFs, the same USD model basis, at least one material non-market factor, and 100% overlap in statistically significant material factor exposure.

SMB HML
Similarity score
92
Near substitute

The score combines exposure-level distance, factor-vector shape, market-beta closeness, and a small backtested relative-Sharpe term.

Quick Read

  • VBR has the higher backtested relative Sharpe (1.023 vs 0.934).
  • VBR has the lower published fee (0.05% vs 0.10%).
  • VBR is cheaper on dividend valuation (109 vs 114, where 100 is each fund's historical median).
  • VBR has the stronger regression fit (adjusted R-squared 0.974 vs 0.954).

These are screening signals, not a complete review of portfolio construction, turnover, taxes, or trading quality.

IVOV

Vanguard S&P Mid-Cap 400 Value ETF
SMB HML
Adj. R2
0.954
Rel. Sharpe
0.934
Mkt beta
1.00
AUM
US$1.2B
MER
0.10%
Valuation
114

VBR

Vanguard Small Cap Value ETF
SMB HML
Adj. R2
0.974
Rel. Sharpe
1.023
Mkt beta
1.00
AUM
US$33.7B
MER
0.05%
Valuation
109

Factor Exposure Match

Blue bars compare raw factor beta magnitude. Green bars compare absolute t-stat strength. Dim bars indicate the t-stat is below 1.96.

SMB
IVOV
+0.52
|t|
+13.9
VBR
+0.61
|t|
+25.2
diff -0.09
HML
IVOV
+0.34
|t|
+9.2
VBR
+0.32
|t|
+13.3
diff +0.02
RMW
IVOV
+0.17
|t|
+4.0
VBR
+0.13
|t|
+4.5
diff +0.04
CMA
IVOV
+0.02
|t|
+0.5
VBR
+0.04
|t|
+1.2
diff -0.02
UMD
IVOV
-0.08
|t|
-3.2
VBR
-0.04
|t|
-2.7
diff -0.05

Why This Pair Matches

Exposure level
91
Exposure shape
99
Mkt beta diff
0.00
Rel. Sharpe diff
0.089

This comparison focuses on measured factor exposure. It does not compare holdings methodology, turnover, tax handling, or issuer process. Backtested relative Sharpe is a secondary signal rather than a stand-alone forecast. See methodology.

IVOV fund page VBR fund page US ETF Leaders US Universe
Important context

VerifiedBeta publishes educational ETF research, not personalized investment advice, portfolio management, or security recommendations. Funds that screen well here can still be unsuitable for your objectives, taxes, liquidity needs, or constraints. Review fund documents, methodology assumptions, and your own circumstances before acting. See the full disclaimer.